Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00660725 · ClinicalTrials.gov registry record · Phase 1
Study of GemOx and Vandetanib in Advanced Solid Malignancy
A Phase 1 study of Advanced Incurable Solid Malignancy, sponsored by Leonard Appleman.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT00660725: Completed Phase 1 study of Advanced Incurable Solid Malignancy, sponsored by Leonard Appleman.
NCT00660725 is a Phase 1 study of Advanced Incurable Solid Malignancy that has completed, run by Leonard Appleman. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00660725, a Phase 1 study of Advanced Incurable Solid Malignancy, has completed, sponsored by Leonard Appleman.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a research study that will try to find the highest and safest dose of an experimental drug, vandetanib, that can be given in combination with two standard chemotherapy agents, gemcitabine and oxaliplatin, to subjects with advanced solid malignancies.
Conditions Studied
Interventions
- DRUG Oxaliplatin
- DRUG Gemcitabine
- DRUG Vandetanib
Study Locations (1)
Pennsylvania
- University of Pittsburgh Cancer Institute / Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
What the finished NCT00660725 record still lists
NCT00660725 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Advanced Incurable Solid Malignancy appearing as the primary indexed condition, and to 3 interventions - of which Oxaliplatin is the first listed.
NCT00660725 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00660725 about?
NCT00660725 is a clinical study titled "Study of GemOx and Vandetanib in Advanced Solid Malignancy". This is a research study that will try to find the highest and safest dose of an experimental drug, vandetanib, that can be given in combination with two standard chemotherapy agents, gemcitabine and oxaliplatin, to subjects with advanced solid malignancies.
What is the current status of trial NCT00660725?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2009-02. Estimated completion is 2010-12.
What conditions does trial NCT00660725 study?
This clinical trial studies the following conditions: Advanced Incurable Solid Malignancy.
What interventions are being tested in trial NCT00660725?
The interventions under investigation include: Oxaliplatin (DRUG), Gemcitabine (DRUG), Vandetanib (DRUG).
Who is sponsoring clinical trial NCT00660725?
This trial is sponsored by Leonard Appleman, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00660725 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00660725's enrollment target sits among peer trials
22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia